×
About 4,755 results

ALLMedicine™ Angioedema Center

Research & Reviews  1,221 results

Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.
https://doi.org/10.1007/s12016-021-08886-x 10.1111/all.14037 10.1111/all.13397 10.1016/j.alit.2018.05.011 10.1111/bjd.19561 10.1016/j.jaad.2019.02.034 10.1111/imr.12632 10.1007/s12016-017-8628-1 10.1111/all.13949 10.1007/s12016-012-8326-y 10.1172/jci85538 10.1111/j.1365-2133.1986.tb04065.x 10.1067/mai.2001.117792 10.1371/journal.pone.0014794 10.1016/j.jaci.2017.10.035 10.1111/all.13832 10.3389/fimmu.2018.00689 10.1038/s41385-020-00336-9 10.1111/all.13567 10.1016/j.jaci.2018.05.019 10.1067/mai.2002.120954 10.1111/j.1365-2222.2005.02380.x 10.1067/mai.2001.114656 10.1111/all.14412 10.1016/j.jaci.2016.04.036 10.1016/j.autrev.2017.10.003 10.1111/j.1398-9995.2012.02879.x 10.1111/all.12786 10.1111/j.1600-065X.2008.00742.x 10.1016/j.jaci.2007.08.051 10.3389/fimmu.2019.00627 10.1016/j.jaci.2005.12.1343 10.1016/j.jaci.2006.08.043 10.1111/j.1398-9995.2009.02222.x 10.1159/000155748 10.1016/j.jaci.2020.08.018 10.1016/s0091-6749(99)70190-9 10.1007/s11739-009-0333-5 10.1016/j.jaad.2018.02.033 10.1186/s13601-018-0234-7 10.1111/all.13110 10.1097/ACI.0b013e32833c79d7 10.1007/s40257-015-0152-6 10.1111/hel.12661 10.1111/hel.12312 10.1007/s40257-020-00561-9 10.1111/all.13381 10.1111/j.1365-2133.2009.09411.x 10.1111/all.13482 10.1016/j.jaci.2016.04.051 10.1016/j.jaci.2014.05.004 10.1111/all.14015 10.2332/allergolint.13-OA-0536 10.1067/mai.2002.121309 10.1159/000339332 10.1111/bjd.13621 10.1016/j.molimm.2010.10.010 10.1159/000496162 10.1111/all.13586 10.1016/j.jaci.2014.02.036 10.1111/bjd.14768 10.1111/bjd.15104 10.1016/j.jdermsci.2019.05.008 10.2340/00015555-2941 10.1016/j.jaci.2013.04.037 10.1186/s13601-019-0275-6 10.23822/eurannaci.1764-1489.05 10.1016/j.jaci.2016.10.017 10.1111/exd.13874 10.1016/j.jaad.2020.02.041 10.1111/pai.13325 10.1038/nrd1334 10.1016/j.jaci.2015.12.1342 10.1007/s12016-020-08794-6 10.1016/j.anai.2019.11.028 10.1111/ced.13173 10.1111/all.13675 10.1016/j.jaci.2017.10.018 10.1016/j.jaip.2020.02.012 10.1016/j.jaci.2016.03.030 10.1016/j.jaci.2017.07.013 10.1016/j.jaci.2011.04.010 10.1684/ejd.2018.3454 10.1172/jci129697 10.1016/j.jaci.2017.08.007 10.2340/00015555-2654 10.1111/all.13936 10.1016/j.jaci.2016.07.047 10.1016/j.jaci.2016.08.050 10.1111/all.14033 10.1016/j.jaip.2020.08.048 10.1016/j.alit.2019.10.009 10.1111/all.14702 10.1111/bjd.19312 10.1111/all.14686 10.1016/j.jaci.2014.08.025 10.1016/j.jaci.2019.05.019 10.1159/000509179 10.1046/j.1365-2133.2000.03664.x 10.1016/j.jaip.2017.07.017 10.1111/bjd.17005 10.1016/j.alit.2018.09.006 10.1016/j.jaip.2013.06.003 10.4103/0378-6323.129382 10.1016/j.jaad.2019.07.097 10.1016/j.jaad.2011.06.004 10.1111/j.1365-4632.2006.02655.x 10.1111/ijd.12536 10.1016/j.jaip.2018.12.023 10.1111/j.1365-2222.2004.02019.x 10.1016/j.jaci.2004.06.018 10.1080/09546634.2017.1329505 10.1016/j.jaip.2014.06.004 10.1001/jamadermatol.2018.3715 10.1111/j.1365-2230.1994.tb01168.x 10.1016/j.jdermsci.2017.08.007 10.5935/0305-7518.19910020 10.23822/EurAnnACI.1764-1489.11 10.4103/ijd.IJD_710_16 10.1159/000458152 10.1111/phpp.12008 10.1111/bjd.14778 10.1016/j.jaip.2016.08.010 10.1111/cea.12400 10.1056/NEJMoa1900408 10.1056/NEJMc2016395 10.1016/j.jaip.2018.11.018 10.1111/all.12884 10.1111/all.13878 10.1016/j.jaip.2016.09.029 10.1111/all.14674 10.1016/j.jaip.2015.09.021 10.1111/jdv.13765 10.1016/j.jaip.2018.12.025 10.2332/allergolint.13-OA-0611 10.1016/j.jaci.2017.01.043 10.1016/j.ceca.2010.09.001 10.1016/j.ceca.2011.08.003 10.1016/j.jaip.2020.04.042 10.1034/j.1398-9995.2000.00445.x 10.1016/j.jaci.2017.01.042 10.1111/j.1365-2133.1987.tb04898.x 10.1016/j.jaci.2017.06.032 10.1016/j.jaip.2014.07.008 10.1016/s0140-6736(79)92664-3 10.2332/allergolint.10-OA-0269 10.1111/j.1365-2133.1975.tb03057.x 10.1016/j.jaci.2018.01.031 10.1016/j.jaci.2019.02.005 10.1016/j.jaip.2020.03.004 10.1016/j.jaip.2020.05.016 10.1016/j.jdermsci.2017.02.283 10.1016/j.jaad.2015.11.021 10.1016/j.jaci.2018.08.050 10.1016/j.jaip.2018.02.032 10.1111/bjd.19425 10.1111/bjd.14820 10.1016/j.jaad.2006.04.078 10.1016/j.anai.2017.07.029 10.1016/j.anai.2019.01.006 10.1016/j.waojou.2019.100033 10.4103/2229-5178.156391 10.1001/archderm.142.10.1337 10.1016/j.anai.2013.09.028 10.1067/mai.2002.126676 10.1016/j.jaip.2018.04.026 10.1016/j.anai.2009.12.007 10.1080/000155500750043131 10.2340/00015555-0434 10.3109/09546634.2011.593485 10.1111/cea.13102
Clinical Reviews in Allergy & Immunology; He L, Yi W et. al.

Sep 17th, 2021 - Chronic urticaria (CU) is a common skin condition characterized by the recurrence of wheals, with or without angioedema, which lasts for at least 6 weeks. Owing to its pruritus and incurability, this disease adversely affects the patients' physica...

Hereditary Angioedema of the Small Bowel.
https://doi.org/10.1007/s11605-021-05135-6 10.1056/NEJMra1808012 10.2500/aap.2019.40.4267
Journal of Gastrointestinal Surgery : Official Journal Of... Huang WF, Yu J et. al.

Sep 11th, 2021 - Hereditary Angioedema of the Small Bowel.|2021|Huang WF,Yu J,Liu W,|

Variability of disease activity in patients with hereditary angioedema type 1/2: longit...
https://doi.org/10.1111/jdv.17654
Journal of the European Academy of Dermatology and Venere... Maurer M, Caballero T et. al.

Sep 11th, 2021 - Hereditary angioedema due to C1 inhibitor deficiency (HAE-1/2) is a chronic and debilitating disease. The unpredictable clinical course represents a significant patient burden. To analyze longitudinal registry data from the Icatibant Outcome Surve...

gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema.
https://doi.org/10.1007/s10753-021-01532-w 10.1097/WOX.0b013e31817aecbe 10.1016/0091-6749(83)90052-0 10.1016/j.clim.2004.05.007 10.1078/0171-2985-00143 10.1016/j.molimm.2004.03.014 10.1006/clim.1999.4753 10.1007/0-387-34134-X_7 10.1016/j.molimm.2010.05.010 10.1161/01.RES.70.5.1018 10.1172/JCI200214211 10.1016/0006-2952(86)90727-6 10.1111/j.1476-5381.1995.tb15108.x 10.3390/pharmacy6020043 10.1161/01.CIR.101.15.1867 10.1038/sj.bjp.0702328 10.1016/j.molimm.2006.11.012 10.1016/j.thromres.2007.11.005 10.1098/rsif.2011.0177 10.2147/TCRM.S3172 10.1016/j.jaci.2009.08.007 10.1089/hyb.1996.15.333 10.1111/j.1538-7836.2006.02065.x 10.1016/j.thromres.2010.11.021 10.3109/09537104.2011.585257 10.1016/j.thromres.2016.12.003 10.4049/jimmunol.173.11.6921 10.1111/jdi.12162 10.1007/s12195-019-00585-0 10.1084/jem.147.2.488 10.3389/fbioe.2020.00369 10.1114/1.1385811 10.1016/j.cardiores.2007.04.017 10.3389/fcell.2019.00044 10.4049/jimmunol.168.5.2441 10.1160/TH03-04-0231 10.1097/TME.0000000000000211 10.1016/j.jemermed.2012.07.055 10.1016/S1567-5769(02)00162-5 10.1111/j.1476-5381.1967.tb02148.x 10.1152/ajpheart.2001.281.1.H275 10.1016/j.molimm.2017.01.028 10.1016/j.jaci.2013.12.1072 10.1016/j.jaci.2011.02.017 10.3389/fimmu.2011.00058 10.1016/j.iac.2013.07.008 10.1007/978-1-4614-4118-2_6 10.1016/j.jaci.2010.08.012
Inflammation Fandaros M, Joseph K et. al.

Sep 9th, 2021 - Angioedema is characterized by swelling of the skin or mucous membranes. Overproduction of the vasodilator bradykinin (BK) is an important contributor to the disease pathology, which causes rapid increase in vascular permeability. BK formation on ...

Urticaria and angioedema associated with SARS-CoV-2 infection.
https://doi.org/10.1503/cmaj.211087
CMAJ : Canadian Medical Association Journal = Journal De ... Zipursky JS, Croitoru D

Sep 9th, 2021 - Urticaria and angioedema associated with SARS-CoV-2 infection.|2021|Zipursky JS,Croitoru D,|diagnosis,drug therapy,etiology,therapeutic use,complications,diagnosis,therapeutic use,isolation & purification,diagnosis,drug therapy,etiology,

see more →

Guidelines  4 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Soc... Moellman JJ, Bernstein JA et. al.

Apr 16th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 4th, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

International consensus and practical guidelines on the gynecologic and obstetric manag...
https://doi.org/10.1016/j.jaci.2011.11.025
The Journal of Allergy and Clinical Immunology; Caballero T, Farkas H et. al.

Dec 27th, 2011 - There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). We sought to elaborate guidelines for optimizing the managem...

see more →

Drugs  525 results see all →

News  152 results

FDA Approves Myrbetriq to Treat Pediatric NDO
https://www.medscape.com/viewarticle/948305

Mar 29th, 2021 - The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurologic impairment, in children aged 3 years a...

FDA Approvals, Highlights, and Summaries
https://reference.medscape.com/viewarticle/945186

Feb 24th, 2021 - Allergy/Immunology Orladeyo (berotralstat) Berotralstat is the first oral kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 years and older. Kallikrein is a protease that cleaves high-molecula...

Fast Five Quiz: Food Allergies
https://reference.staging.medscape.com/viewarticle/936716_3

Sep 8th, 2020 - Although anaphylaxis can occur without skin symptoms, cutaneous reactions are the most common clinical manifestations of an allergic reaction to a food or food additive. Peanuts remain the most common cause of severe food allergy symptoms and anap...

For Patients with HFrEF, What Is the Role for and Treatment Pearls for ARNI?
https://decisionpoint.medscape.com/cardiology/viewarticle/926451

May 21st, 2020 - This transcript has been edited for clarity. The data with angiotensin receptor neprilysin inhibitor (ARNI) therapy, valsartan sacubitril, continue to evolve in terms of its role in the patient’s management with heart failure reduced ejection frac...

Simple Decision Rule Helps Identify People at Low-Risk for Penicillin Allergy
https://www.staging.medscape.com/viewarticle/926960

Mar 18th, 2020 - NEW YORK (Reuters Health) - A simple clinical decision rule for penicillin allergy can help doctors and antimicrobial-stewardship programs identify people at low-risk of penicillin allergy at the point of care, report doctors from Australia who de...

see more →